Epigral reported its highest-ever quarterly revenue of INR736 crore, a 22% QoQ growth, driven by 15% volume growth.
EBITDA surged 64% QoQ to INR169 crore with margins normalizing to 23% due to optimized plant utilization and stable raw material costs.
Management guided for 10-12% volume growth in FY27, with major capacity expansions for Epichlorohydrin and CPVC on track for Q2 FY27 commissioning.
The company acknowledged global supply chain disruptions from West Asia conflict but expects its diversified product portfolio to provide resilience.